Stem cell transplant (SCT) is the only treatment that can cure chronic myelomonocytic leukemia (CMML). In this treatment, the patient gets high-dose chemotherapy often along with radiation to the entire body to kill the cells in the bone marrow (including the abnormal bone marrow cells). Then the patient is given new, healthy blood-forming stem cells. The 2 main types of SCT are: allogeneic and autologous.
In an autologous stem cell transplant, after the bone marrow is destroyed, the patient gets back their own stem cells. This type of transplant is not a standard treatment for patients with CMML because their bone marrow has abnormal stem cells.
For an allogeneic stem cell transplant, the patient gets blood-forming stem cells from another person -- the donor. The best results are when the donor’s cells are closely matched to the patient’s cell type and the donor is closely related to the patient, such as a brother or sister. Less often, an unrelated donor is matched to the patient.
Allogeneic stem cell transplant can have serious, even fatal, side effects and so is rarely used in elderly patients. Because of these side effects, some doctors only use this treatment for people younger than a certain age.
A special type of allogeneic transplant, a non-myeloablative allogeneic stem cell transplant, may be an option for older patients. This type of transplant is sometimes called a mini-transplant or a mini-allo. In this type, the doses of chemo and/or radiation that are given are lower than those used for a standard allogeneic transplant. These doses are not high enough to kill all the bone marrow cells, but they kill just enough to allow the donor cells to take hold and grow in the bone marrow. The lower doses of chemo and/or radiation cause fewer side effects, which makes this type of transplant easier for older patients to tolerate. Still, it has some serious side effects.
For now, allogeneic SCT is the only treatment that can cure some patients with CMML, but not all patients who get a transplant are cured. And patients can die from complications of this treatment. Also, many people with CMML are not able to get this treatment.
To learn more about stem cell transplants, including how they are done and their potential side effects, see Stem Cell Transplant for Cancer.
For more general information about side effects and how to manage them, see Managing Cancer-related Side Effects.
The American Cancer Society medical and editorial content team
Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.
Benton CB, Nazha A, Pemmaraju N, Garcia-Manero G. Chronic myelomonocytic leukemia: Forefront of the field in 2015. Crit Rev Oncol Hematol. 2015;95(2):222-242.
de Witte T, Bowen D, Robin M, et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood. 2017;129(13):1753-1762.
Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management. Am J Hematol. 2016;91(6):631-642.
Last Revised: October 25, 2017
American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.
